Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Overview of attention for article published in Journal of Clinical Oncology, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 44 news outlets
blogs: 16 blogs
policy: 1 policy source
twitter: 98 X users
patent: 93 patents
facebook: 13 Facebook pages

wikipedia: 10 Wikipedia pages
googleplus: 4 Google+ users
reddit: 8 Redditors
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 1571 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 49 news stories from 44 outlets.

From Coley’s Toxins to mRNA: Reflecting on the History of Cancer Vaccines

Pharma's Almanac, 02 Mar 2025

Over the past three decades, cancer vaccines have evolved from experimental concepts to transformative tools in oncology.

T-VEC improved durable response rate in advanced melanoma

Pediatric News , 01 Jan 2025

FROM JOURNAL OF CLINICAL ONCOLOGY Treatment with the oncolytic immunotherapy talimogene laherparepvec (T-VEC) resulted in…

瘤内免疫疗法临床试验比较

CN-Healthcare, 27 Nov 2022

A- A+ SAR441000 (BTN131)：是一种免疫刺激mRNA混合物，编码IL-12sc、IL-15、IFN-α和粒细胞-巨噬细胞集落刺激因子GMCSF。目前仅公布了首次人体试验的剂量安全性检测阶段结果。瘤内(Intratumoral, IT)免…

Genetically engineered, cancer-killing herpes virus may be able to…

Medical News Today, 30 Sep 2022

Share on PinterestScientists are trying to use viruses to fight off cancerous tumors.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 45 additional news stories.